{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/parvovirus-b19-infection/background-information/prognosis/","result":{"pageContext":{"chapter":{"id":"034c66fb-a99f-5a21-a031-d557dc647301","slug":"prognosis","fullItemName":"Prognosis","depth":2,"htmlHeader":"<!-- begin field 488bb165-8a99-4113-8cbe-998bb1497efc --><h2>What is the prognosis?</h2><!-- end field 488bb165-8a99-4113-8cbe-998bb1497efc -->","summary":"","htmlStringContent":"<!-- begin item bf69ef23-dcda-4276-922a-d289ab2bd1d2 --><!-- begin field fdca6aa4-7195-4419-9c38-ce63597c1162 --><ul><li><strong>For most healthy people,</strong> parvovirus B19 infection causes a mild, self-limiting illness which is followed by life-long immunity.<ul><li>In children, an erythematous <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/diagnosis/diagnosis/\">rash</a> affecting the trunk and limbs may recur months after the acute infection, following exposure to sunlight, heat, stress, or exercise.</li><li>In adults, a <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/diagnosis/diagnosis/\">symmetrical polyarthropathy</a> may persist for months (or very rarely years) after the acute infection, or may recur several months after the acute infection.</li></ul></li><li><strong>For pregnant women</strong> with confirmed parvovirus B19 infection, the prognosis partially depends on the gestational age at infection. The risk of transmission to the fetus is increased between 9–20 weeks' gestation.<ul><li>Transplacental transmission occurs in about 30% of women depending on gestation, with a mean of about 6 weeks between maternal infection and fetal symptoms.</li><li>The fetus is most vulnerable when it is infected in the second trimester, with the peak risk occurring at 17–24 weeks' gestation.</li><li>At less than 20 weeks' gestation, the estimated excess fetal loss rate during pregnancy is about 9%.</li><li>Babies who are born at full term are usually healthy with no evidence of congenital malformations or developmental problems secondary to infection.</li></ul></li><li><strong>For people who are immunocompromised,</strong> they may develop persistent infection and are at increased risk of <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/background-information/complications/\">haematological complications</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">HPA, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">Slavov, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">UK National Screening Committee, 2014</a>]</p><!-- end field fdca6aa4-7195-4419-9c38-ce63597c1162 --><!-- end item bf69ef23-dcda-4276-922a-d289ab2bd1d2 -->","topic":{"id":"a0e6adce-f85f-55b0-8d7f-3b5e75836d40","topicId":"3ea4cf87-3eee-4e3f-a6d0-b0ee3a4ee3ad","topicName":"Parvovirus B19 infection","slug":"parvovirus-b19-infection","lastRevised":"Last revised in February 2017","chapters":[{"id":"c45face5-dc30-586a-b7ca-3b24305bd068","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cc09231e-bb7a-5379-aeec-7c830288098e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2971cfc1-4839-5be6-b726-20b9383ae294","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"020d2cdb-0f7f-5bc0-a249-98fc3690b68c","slug":"changes","fullItemName":"Changes"},{"id":"af1bc49c-d614-521b-b6f3-ad084fc2aed9","slug":"update","fullItemName":"Update"}]},{"id":"7c9f0c10-cf1d-5723-856f-e0bc2d270210","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb1635ce-433b-5f39-a93a-27b4488878c5","slug":"goals","fullItemName":"Goals"},{"id":"3c7eed51-287a-5bcb-8519-40ef7f5784aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"291f85a1-8911-59d4-82d6-62ce4daff1c0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e66b8854-eb00-59b9-85d9-f50343f36470","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce817770-4fbe-5b47-b4ed-56b723012488","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"faa5c5db-5837-5cbd-8e56-78bc7ac42137","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0f0e8f26-e2c7-5de3-b012-e340b25ad622","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"afcf1b63-41ac-5295-91b5-4e19bc828249","slug":"definition","fullItemName":"Definition"},{"id":"60a93741-3863-58bb-8394-a33804062373","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1cfa61b6-71af-5e94-9e40-95b29e9f97dc","slug":"complications","fullItemName":"Complications"},{"id":"034c66fb-a99f-5a21-a031-d557dc647301","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"53019719-ec11-57d5-afd3-3ed2e9939168","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7eca192-b219-5e71-8ecd-6d2e6cf0f3da","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"2b824d0f-b0b0-5801-8def-a38d172c2532","slug":"investigations","fullItemName":"Investigations"},{"id":"7daba43a-1410-5703-8a94-b6530a5dfccc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b0275eae-f19c-57fb-834c-03df7c6dcea3","fullItemName":"Management","slug":"management","subChapters":[{"id":"73c2e9d4-b567-504f-9b28-36966a247590","slug":"children-adults-not-pregnant","fullItemName":"Scenario: Children and adults (not pregnant)"},{"id":"25b4fecb-ae9d-58f7-ad14-7ace595c0800","slug":"pregnant-women","fullItemName":"Scenario: Pregnant women"}]},{"id":"bdf3d270-5563-5eb4-804f-68fce2e7e7dd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"73875656-8429-5584-82e6-d06c0a5f52ea","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8dc117ba-c373-5ee0-a7aa-fc63a62a7067","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"24bd5691-28ce-53b1-be8b-f0e51e40db4b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6b35b969-66a8-5431-900a-a524f0bf1a89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"63ad51a8-8325-52f2-a254-ed3ccae9f508","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"174a35a7-6fa3-58ef-9e06-6325d5f0111b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c6c0fc6f-31f8-5681-bbce-4ed5b6b16e4e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0f0e8f26-e2c7-5de3-b012-e340b25ad622","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}